Please use this identifier to cite or link to this item:
|Title:||Targeted Therapies for Microvascular Disease||Authors:||Bland, Adam ;Chuah, Eunice ;Meere, William||Affliation:||Central Coast Local Health District
|Issue Date:||Jan-2023||Source:||12(1):131-139||Journal title:||Interventional Cardiology Clinics||Department:||Cardiology||Abstract:||Coronary microvascular dysfunction (CMD) is a common cause of ischemia but no obstructive coronary artery disease that results in an inability of the coronary microvasculature to meet myocardial oxygen demand. CMD is challenging to diagnose and manage due to a lack of mechanistic research and targeted therapy. Recent evidence suggests we can improved patient outcomes by stratifying antianginal therapies according to the diagnosis revealed by invasive assessment of the coronary microcirculation. This review article appraises the evidence for management of CMD, which includes treatment of cardiovascular risk, antianginal therapy and therapy for atherosclerosis.||URI:||https://hdl.handle.net/1/2277||DOI:||10.1016/j.iccl.2022.09.011||Pubmed:||https://pubmed.ncbi.nlm.nih.gov/36372457/||Publicaton type:||Journal Article||Keywords:||Cardiology
|Appears in Collections:||Cardiology|
Show full item record
checked on Sep 29, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.